Application No. 10/581,495 Amendment dated April 9, 2009

Reply to Office Action of December 9, 2009

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A smallpox vaccinia vaccine virus generated from a vaccinia

virus LC16 strain, LC16m8 strain or LC16mO strain undergoing with difficulty reverse mutation

that induces production of a B5R gene product having normal functions, which is a smallpox

vaccinia vaccine virus being deficient in a part or the whole of a B5R gene of a vaccinia virus

LC16 strain, LC16m8 strain, or LC16mO strain and consisting of a vaccinia virus that produces

no B5R gene products having normal functions.

2. (Currently Amended) The smallpox vaccinia vaccine virus according to claim 1,

which is completely deficient in the B5R gene.

3. (Currently Amended) The smallpox vaccinia vaccine virus according to claim 1,

which is deficient in a part of the B5R gene and produces no B5R gene expression products

having normal functions.

4. (Currently Amended) The smallpox vaccinia vaccine virus according to claim 1,

wherein plaque sizes resulting from infection of RK13 cells with the virus and subcutaneous

proliferation property resulting from administration of the virus to a rabbit are equivalent to those

of the LC16m8 strain.

2

GMM/LTP/smj

Docket No.: 1254-0315PUS1

- 5. (Currently Amended) The smallpox vaccinia vaccine virus according to claim 1, which is deficient in a part of the B5R gene, wherein a promoter is ligated upstream of the B5R gene and a part of the B5R gene is expressed, but the expression product lacks the normal functions of a B5R gene expression product.
- 6. (Currently Amended) The smallpox vaccinia vaccine virus according to claim 3, which is deficient in a transmembrane domain of the B5R gene.
- 7. (Currently Amended) The smallpox vaccinia vaccine virus according to claim 5, wherein the promoter is PSFJ1-10, PSFJ2-16, or another high expression promoter for poxvirus.
 - 8.-10. (Canceled).
- 11. (Currently Amended) A smallpox vaccine pharmaceutical composition, which contains the smallpox vaccinia vaccine virus according to claim 1.
- 12. (Currently Amended) A vaccinia virus vector generated from a vaccinia virus LC16 strain LC16m8 strain, or LC16mO strain, undergoing with difficulty reverse mutation that induces production of a B5R gene product having normal functions, which is a vaccinia virus vector being deficient in a part or the whole of a B5R gene of a vaccinia virus LC16 strain, LC16m8 strain, or LC16mO strain and producing no B5R gene products having normal functions.

13. (Original) The vaccinia virus vector according to claim 12, which is completely

deficient in the B5R gene.

14. (Previously Amended) The vaccinia virus vector according to claim 12, which is

deficient in a part of the B5R gene and produces no B5R gene expression products having

normal functions.

15. (Previously Amended) The vaccinia virus vector according to claim 12, wherein

plaque sizes resulting from infection of rabbit kidney cells with the vector and subcutaneous

proliferation property resulting from administration of the vector to a rabbit are equivalent to

those of the LC16m8 strain.

16. (Previously Amended) The vaccinia virus vector according to claim 12, which is

deficient in a part of the B5R gene, wherein a promoter is ligated upstream of the B5R gene and

a part of the B5R gene is expressed, but the expression product lacks the normal functions of a

B5R gene expression product.

17. (Currently Amended) The vaccinia virus vector according to claim [[12]] 14, which

is deficient in a transmembrane domain of the B5R gene.

18. (Previously Presented) The vaccinia virus vector according to claim 16, wherein the

promoter is PSFJ1-10, PSFJ2-16, or another high expression promoter for poxvirus.

4

GMM/LTP/smj

Docket No.: 1254-0315PUS1

Docket No.: 1254-0315PUS1

19-21. (Canceled)

22. (Currently Amended) The vaccinia virus vector according to claim 12, which contains at least one [[a]] foreign gene.

23. (Original) The vaccinia virus vector according to claim 22, wherein the foreign gene is an antigen of a virus, a bacterium, a protozoan, or cancer.

24. (Currently Amended) A vaccine virus pharmaceutical composition for a virus, a bacterium, a protozoan, or cancer, which contains the vaccinia virus vector according to claim 23.

5